Mononucleoside phosphorodithiolates as mononucleotide prodrugs - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2022

Mononucleoside phosphorodithiolates as mononucleotide prodrugs

Résumé

The synthesis and in vitro anti-HIV activity of a novel series of pronucleotides are reported. These prodrugs were characterized by a phosphorodithiolate structure, incorporating two O-pivaloyl-2-oxyethyl substituents as biolabile phosphate protections. The compounds were obtained following an original one-pot three-step procedure, involving the formation of a phosphorodithioite intermediate which is in situ oxidized. In vitro, comparative anti-HIV evaluations demonstrate that such original prodrugs are able to allow the efficient intracellular release of the corresponding 5 0-mononucleotide. The pronucleotide of 2 0 ,3 0-dideoxyadenosine (ddA) 3 exhibited a very potent antiretroviral effect with 50% effective concentration (EC 50) values in nanomolar concentration range in various cell lines. In primary monocytes/ macrophages, this derivative was 500 times more potent in inhibiting HIV replication (EC 50 0.23 pM) than ddA and the selectivity index of the prodrug is fifty times higher than the one of the parent nucleoside.
Fichier principal
Vignette du fichier
2022 EurJMedChem v227 p113914 NS.pdf (1010.43 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03811171 , version 1 (11-10-2022)

Identifiants

Citer

Nathalie Schlienger, Isabelle Lefebvre, Anne-Marie Aubertin, Suzanne Peyrottes, Christian Périgaud. Mononucleoside phosphorodithiolates as mononucleotide prodrugs. European Journal of Medicinal Chemistry, 2022, 227, pp.113914. ⟨10.1016/j.ejmech.2021.113914⟩. ⟨hal-03811171⟩
4 Consultations
8 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More